GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Isofol Medical AB (OSTO:ISOFOL) » Definitions » Cash And Cash Equivalents

Isofol Medical AB (OSTO:ISOFOL) Cash And Cash Equivalents : kr128.49 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Isofol Medical AB Cash And Cash Equivalents?

Isofol Medical AB's quarterly cash and cash equivalents declined from Sep. 2023 (kr144.23 Mil) to Dec. 2023 (kr138.15 Mil) but then stayed the same from Dec. 2023 (kr138.15 Mil) to Mar. 2024 (kr128.49 Mil).

Isofol Medical AB's annual cash and cash equivalents declined from Dec. 2021 (kr379.45 Mil) to Dec. 2022 (kr190.53 Mil) and declined from Dec. 2022 (kr190.53 Mil) to Dec. 2023 (kr138.15 Mil).


Isofol Medical AB Cash And Cash Equivalents Historical Data

The historical data trend for Isofol Medical AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isofol Medical AB Cash And Cash Equivalents Chart

Isofol Medical AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only 126.98 116.39 379.45 190.53 138.15

Isofol Medical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 163.96 156.77 144.23 138.15 128.49

Isofol Medical AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Isofol Medical AB  (OSTO:ISOFOL) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Isofol Medical AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Isofol Medical AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Isofol Medical AB (OSTO:ISOFOL) Business Description

Traded in Other Exchanges
Address
Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.

Isofol Medical AB (OSTO:ISOFOL) Headlines

No Headlines